Arvinas Shares Dive on Trial Results for Metastatic Breast Cancer Treatment
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer. Shares were trading around $10.35. The stock is down 61% over the last year.
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...
MLive - GrandRapids/Muskegon/Kalamazoo on MSN15h
Pfizer sells park land to Portage for $1PORTAGE, MI — Portage plans to purchase land along Portage Creek for $1. Pfizer owned the vacant, 4.6-acre lot at 6510 Lovers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback